Navigation Links
Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath's Phase III Clinical Trial
Date:9/11/2009

NEW YORK, Sept. 11 -- /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the Data and Safety Monitoring Board ("DSMB") reviewed clinical data on 77 patients enrolled in its pivotal Phase III clinical trial and unanimously recommended that the trial continue to enroll patients with the goal of reaching the 92 patients required to complete the study. In addition, the Company announced it now expects enrollment to be completed by mid-October.

Eamonn Hobbs, President and CEO of Delcath Systems stated, "We are pleased by the successful review of our safety data and the recent, accelerated pace of enrollment, which has put us in the trial's home stretch. This is an exciting time for the Company. With current enrollment trends, we now expect to complete enrollment by the middle of October and are still on track for an FDA submission by mid-2010."

The DSMB is an independent group of experts with the responsibility for reviewing and evaluating the safety and response data generated from the Company's Phase III trial. The primary responsibilities of the DSMB are to ensure the safety of all patients enrolled in the trial, the quality of the data collected and the continued scientific validity of the trial design. The DSMB reviews data periodically in order to make an informed risk versus benefit recommendation concerning the continuation, modification, or termination of the trial due to safety concerns. This DSMB review was triggered upon randomization of the 77th patient which marks the 75% enrollment point for the trial.

About the Phase III Study

This clinical study is testing the Delcath PHP Syste
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
2. July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
3. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
4. 5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
5. Sanofi-aventis Stands Behind the Safety of Lantus(R)
6. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
7. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
8. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
9. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
10. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... a first-in-human Phase 1 clinical trial of APD597, a ... the glucose-dependent insulinotropic receptor (GDIR) for the treatment of ... Arena and has the potential to stimulate insulin release ...
... Corporation of North,America today announced that the U.S. ... disodium) Injection, an intravenous,sedative-hypnotic agent for monitored anesthesia ... therapeutic procedures. , ... LUSEDRA be used only by persons,trained in the ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 4FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 2FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 4
(Date:12/24/2014)... The 2014 Market Research Report ... in-depth research report on COC industry. For an ... including its definition, classification, application, industry chain structure, ... report also presents product specification, manufacturing process, and ... regions, technology and applications. Analysis also covers upstream ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 For nearly ... blessings, housewarmings, new babies, graces, and all of life's ... poet and author, Nancy Tupper Ling, in Toasts: ... by Viva Editions. , Organized by category and ... that won't appear anywhere else, this timely tome contains ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 “ Relax ... its monthly AppWatch, which features the latest and coolest ... Andrew Tropeano, a mobile technology expert and host of ... how this application soothes users so they can fall ... 30% of adults say they have some sort of ...
(Date:12/24/2014)... Las Vegas, NV (PRWEB) December 24, 2014 ... Home Services reminds homeowners that before investing time ... start by consulting a licensed professional that specializes in ... who may plan to replace their water heater in ... making a final decision. , Greenstar Home Services ...
Breaking Medicine News(10 mins):Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2
... Engineers have developed a new type of microchip muscle stimulator ... paralysed leg muscles. It is the first time ... is small enough to be implanted into the spinal canal ... The implant is the size of a child,s fingernail. ...
... have become aware of the dangers of excessive fructose in ... of the Journal of the American Society of Nephrology ... sugar may be. Richard J. Johnson, MD and ... of Colorado) provide a concise overview of recent clinical and ...
... Nov. 22 (HealthDay News) -- Women who were sexually or ... problems, researchers say. In the study, researchers analyzed data ... U.S. National Alcohol Survey. The investigators found that women who ... more likely to also report that they drank four or ...
... , MONDAY, Nov. 22 (HealthDay News) -- The approximately ... each year in the United States cost the health care ... Control and Prevention said in its annual STD report released ... burden of STDs but there are some signs of progress, ...
... EDITOR,S PICK: Who is in your poo? ... Pamer, Carles Ubdea, and colleagues, at Memorial Sloan-Kettering ... suggest that high-throughput DNA sequencing of bacteria in ... life-threatening bloodstream infection with the antibiotic-resistant bacterium vancomycin-resistant ...
... Alexandria, Va. The American Association for Dental Research (AADR) ... the Washington, DC, area. This year, the theme was the ... & Clinical Frontiers. The symposium was sold-out, but AADR also ... AADR created the Fall Focused Symposium under the objective ...
Cached Medicine News:Health News:New spinal implant will help people with paraplegia to exercise paralyzed limbs 2Health News:Girls Who Suffer Child Abuse May Abuse Alcohol as Adults 2Health News:New STD Report Finds Some Progress, High Costs for U.S. 2Health News:JCI table of contents: Nov. 22, 2010 2Health News:JCI table of contents: Nov. 22, 2010 3Health News:JCI table of contents: Nov. 22, 2010 4Health News:JCI table of contents: Nov. 22, 2010 5Health News:JCI table of contents: Nov. 22, 2010 6Health News:JCI table of contents: Nov. 22, 2010 7Health News:JCI table of contents: Nov. 22, 2010 8Health News:JCI table of contents: Nov. 22, 2010 9Health News:JCI table of contents: Nov. 22, 2010 10Health News:JCI table of contents: Nov. 22, 2010 11Health News:JCI table of contents: Nov. 22, 2010 12Health News:Cutting-edge salivary diagnostics research presented at AADR 3rd Fall Focused Symposium 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: